Inversago Pharma
Specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $1.1b Valuation: $1.1b | Acquisition | |
| Total Funding | 000k | ||
Related Content
Inversago Pharma is a preclinical stage biotech company dedicated to developing new therapies that focus on blocking CB1 receptors in the peripheral nervous system. This approach aims to treat a range of metabolic and fibrotic diseases, including diabetic nephropathy, non-alcoholic steatohepatitis, type 1 diabetes, progressive fibrosing interstitial lung disease, and Prader-Willi syndrome. The company operates in the biotechnology and pharmaceutical markets, primarily serving patients with these specific conditions.
Inversago Pharma's business model revolves around the research and development of first-in-class, peripherally acting CB1 inverse agonists. These inhibitors have the potential to block or reverse the biological processes induced by excessive CB1 activation, offering novel treatment options for patients. The company generates revenue through partnerships, licensing agreements, and potential future sales of their developed therapies.
Keywords: CB1 blockade, metabolic diseases, fibrotic diseases, diabetic nephropathy, non-alcoholic steatohepatitis, type 1 diabetes, interstitial lung disease, Prader-Willi syndrome, biotech, pharmaceutical.